Abstract
Recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF) was the first specific haematopoietic growth factor to be widely available for use in conjunction with cancer chemotherapy. This chapter reviews the development of r-metHuG-CSF as a novel treatment in the management of neutropenia and associated clinical problems in medical oncology.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
